跳至主要內容
MediHelp
MediHelp 藥品參考

藥品參考

Ponatinib

Ponatinib is a medicine in the class oncology. It is used for acute lymphocytic leukemia.

最後更新 來源: US FDA label

僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。

本頁的臨床內容僅提供英文版。

重點資訊

藥物類別
Oncology
ATC 代碼
L01EA05
常見劑型
錠劑
常見規格
15 mg
已知交互作用
114 (嚴重: 18 · 中度: 60 · 輕微: 36)
商品名
3
國家與市場
3

劑型、規格與商品名稱會因國家而異。請核對您手上的產品。

用途

作用方式

Ponatinib is a kinase inhibitor that inhibits ABL and T315I mutant ABL tyrosine kinase activity in vitro, and also inhibits VEGFR, PDGFR, FGFR, EPH receptor and SRC family kinases, KIT, RET, TIE2 and FLT3.

成人常用劑量（仿單摘要）

Newly diagnosed Ph+ ALL: 30 mg orally once daily with chemotherapy; reduce to 15 mg once daily on MRD-negative CR at end of induction; continue up to 20 cycles until loss of response or unacceptable toxicity

僅摘錄仿單中第一行劑量說明；完整的劑量內容請見 App。

懷孕與哺乳

懷孕
Unsafe Can cause fetal harm: no human data; in rats it caused developmental toxicity below human exposure. Avoid in pregnancy; check pregnancy status before starting and use effective contraception during treatment and for 3 weeks after.
哺乳
Unsafe No milk data; it is over 99% protein bound, but its 24-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose (US label); NCCN also advises avoiding breastfeeding.

已通報的副作用

  • Rash and related conditions
  • Arthralgia
  • Abdominal pain
  • Fatigue
  • Headache
  • Constipation

黑框警語

  • Arterial occlusive events, including fatal MI, stroke, large cerebral artery stenosis and severe peripheral vascular disease, occurred, including in patients age 50 years or younger and without cardiovascular risk factors. Venous thromboembolic events, heart failure (including fatalities) and hepatotoxicity (liver failure and death) have occurred. Monitor, and interrupt or discontinue based on severity.

哪些人需要特別留意

  • Hypertension: monitor blood pressure and manage; interrupt, reduce or stop if not controlled.
  • Pancreatitis: monitor serum lipase.
  • Myelosuppression: CBC every 2 weeks for first 3 months, then monthly or as indicated.

請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。

重要交互作用 (114)

All 114 interactions, with severity and what to do

Pro+ 會員專屬

解鎖完整頁面

建立帳號並開始 Pro+ 試用，即可開啟 Ponatinib 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。

  • Dosing by age, kidney and liver function, and further dose lines
  • Renal and hepatic dose adjustments
  • Dosing in older adults
  • How to give it
  • Pharmacokinetics
  • Patient counselling points
  • Food interactions
建立免費帳號 登入

在網頁版免費試用 Pro+ 14 天，無需信用卡。

同類別的其他藥品

常見問題

What is Ponatinib used for?

Ponatinib is a medicine in the class oncology. It is used for Acute lymphocytic leukemia, Leukemia.

What side effects have been reported with Ponatinib?

Rash and related conditions, Arthralgia, Abdominal pain, Fatigue, Headache, Constipation. Serious warning: Arterial occlusive events, including fatal MI, stroke, large cerebral artery stenosis and severe peripheral vascular disease, occurred, including in patients age 50 years or younger and without cardiovascular risk factors.

Can Ponatinib be taken in pregnancy or while breastfeeding?

Pregnancy: Unsafe. Can cause fetal harm: no human data; in rats it caused developmental toxicity below human exposure. Avoid in pregnancy; check pregnancy status before starting and use effective contraception during treatment and for 3 weeks after. Breastfeeding: Unsafe. No milk data; it is over 99% protein bound, but its 24-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose (US label); NCCN also advises avoiding breastfeeding.

What does Ponatinib interact with?

MediHelp lists 114 known interactions for Ponatinib. Major: 18 · Moderate: 60 · Minor: 36. The most serious include Apalutamide, Carbamazepine, Chloramphenicol.

在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查

在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。

下載於App Store 立即下載Google Play

依 A–Z 瀏覽 · 藥品參考

取得 App 登入